PT - JOURNAL ARTICLE AU - Song, Jiali AU - Wang, Xiu-Ling AU - Wang, Bin AU - Gao, Yan AU - Liu, Jia-Min AU - Zhang, Hai-Bo AU - Li, Xi AU - Li, Jing AU - Wang, Ji-Guang AU - Cai, Jun AU - Herrin, Jeph AU - Armitage, Jane AU - Krumholz, Harlan M. AU - Zheng, Xin AU - , TI - Rationale and design of the Learning Implementation of Guideline-based decision support system for Hypertension Treatment (LIGHT) Trial and LIGHT-ACD Trial AID - 10.1101/2021.03.11.21253427 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.11.21253427 4099 - http://medrxiv.org/content/early/2021/07/02/2021.03.11.21253427.short 4100 - http://medrxiv.org/content/early/2021/07/02/2021.03.11.21253427.full AB - Background Computerized clinical decision support systems (CDSS) are low-cost, scalable tools with the potential to improve guideline-based antihypertensive treatment in primary care, but their effectiveness needs testing in pragmatic trials.Methods The Learning Implementation of Guideline-based decision support system for Hypertension Treatment (LIGHT) trial is a pragmatic, four-stage, cluster-randomized trial conducted in 94 primary care practices in China. For each city-based stage, practices are randomly assigned to either implementation of the CDSS for hypertension management (which guides physicians treatment recommendations based on measured blood pressure and patient characteristics), or usual care. Patients are enrolled during the first 3 months after site randomization and followed for 9 months. The primary outcome is the proportion of hypertension management visits at which guideline-based treatment is provided.In a separate sub-study conducted within the CDSS, with the patient as the unit of randomization, the LIGHT-ACD trial, patients are randomized to receive different initial mono- or dual- antihypertensive therapy. The primary outcome of the LIGHT-ACD trial is the change in blood pressure from the first visit after site randomization to 9 months.Discussion The LIGHT trial will provide evidence on the effectiveness of a CDSS for improving guideline adherence for hypertension management in primary care in China. The sub-study, LIGHT-ACD trial, will provide data on the effect of different initial antihypertensive regimens for blood pressure management in this setting.Trial registration ClinicalTrials.gov, identifier: LIGHT (NCT03636334) and LIGHT-ACD (NCT03587103). Registered on 3 July 2018.Competing Interest StatementDr. Krumholz works under contract with the Centers for Medicare & Medicaid Services to support quality measurement programs; was a recipient of a research grant, through Yale, from Medtronic and the US Food and Drug Administration to develop methods for post-market surveillance of medical devices; was a recipient of a research grant with Medtronic and is the recipient of a research grant from Johnson & Johnson, through Yale University, to support clinical trial data sharing; was a recipient of a research agreement, through Yale University, from the Shenzhen Center for Health Information for work to advance intelligent disease prevention and health promotion; collaborates with the National Center for Cardiovascular Diseases in Beijing; receives payment from the Arnold & Porter Law Firm for work related to the Sanofi clopidogrel litigation, from the Martin/Baughman Law Firm for work related to the Cook IVC filter litigation, and from the Siegfried and Jensen Law Firm for work related to Vioxx litigation; chairs a Cardiac Scientific Advisory Board for UnitedHealth; was a participant/participant representative of the IBM Watson Health Life Sciences Board; is a member of the Advisory Board for Element Science, the Advisory Board for Facebook, and the Physician Advisory Board for Aetna; and is the founder of HugoHealth, a personal health information platform, and co-founder of Refactor Health, an enterprise healthcare AI-augmented data management company. Dr. Jing Li discloses that she is a recipient of research grants from the government of China, through Fuwai Hospital, for research to improve the management of hypertension and blood lipids, and to improve care quality and patient outcomes of cardiovascular disease; is a recipient of research agreements with Amgen, through National Center for Cardiovascular Diseases (NCCD) and Fuwai Hospital, for a multi-centre trial to assess the efficacy and safety of Omecamtiv Mecarbil, and for dyslipidemic patient registration; is a recipient of a research agreement with Sanofi, through Fuwai Hospital, for a multi-centre trial on the effects of sotagliflozin; is a recipient of a research agreement with University of Oxford, through Fuwai Hospital, for a multi-centre trial of empagliflozin; and was a recipient of a research agreement, through NCCD, from AstraZeneca for clinical research methods training.Clinical TrialLIGHT (NCT03636334);LIGHT-ACD (NCT03587103)Funding StatementThis project was supported by the CAMS Innovation Fund for Medical Science (2016-I2M-1-006) and the 111 Project (B16005) from the Ministry of Education of China.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethics committee of Fuwai HospitalAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo data is available. It is our future plan to share the data of this study. However, we are unable to do so at this time.CDSScomputerized clinical decision support systems;EHRelectronic health record;ACEangiotensin-converting enzyme;ARBangiotensin receptor blockers;CCBcalcium channel blockers;Aangiotensin-converting enzyme inhibitor or angiotensin receptor blocker;Ccalcium channel blocker;Ddiuretics.